The old approach treated cholesterol numbers in isolation, prescribing the same target for a healthy thirty year old and a recent heart attack survivor. Modern guidelines flipped that logic. Because absolute benefit from lowering LDL grows with baseline risk, the patients with the most to gain receive the strictest targets.

The Four Risk Tiers

Very high risk covers anyone with documented vascular disease, diabetes with organ damage, severe kidney disease or a calculated ten year fatal risk above ten percent. The target is below fifty five milligrams per deciliter plus at least a halving from baseline. High risk includes markedly elevated single factors such as familial cholesterol disorders or very high pressure, with a target below seventy. Moderate risk, often younger diabetics or calculated risk between one and five percent, aims below one hundred, and low risk below one hundred sixteen.

Why Lower Keeps Winning

Trial after trial, from statins through ezetimibe to PCSK9 inhibitors, shows events falling in step with achieved LDL, with no floor yet found where benefit stops. Mendelian studies of people born with lifelong low LDL show dramatically reduced event rates, suggesting earlier and deeper lowering pays compound interest over decades.

From Target to Treatment

The gap between current and target LDL dictates intensity. A modest gap may close with diet, weight loss and a moderate statin. A wide gap in a very high risk patient usually needs high intensity statin therapy plus ezetimibe, and sometimes an injectable agent. Rechecking lipids four to twelve weeks after any change confirms whether the plan is working.

Targets are guide rails, not grades. A patient who cannot tolerate the ideal regimen still gains from every meaningful reduction achieved.

References

• 2019 ESC EAS Guidelines for the Management of Dyslipidaemias
• 2018 AHA ACC Guideline on the Management of Blood Cholesterol